Literature DB >> 3411499

Chronic intracerebroventricular morphine and lactation in rats: dependence and tolerance in relation to oxytocin neurones.

V C Rayner1, I C Robinson, J A Russell.   

Abstract

1. Acutely, opioids inhibit oxytocin secretion. To study the responses of oxytocin neurones during chronic opioid exposure, forty-five lactating rats were infused continuously from a subcutaneous osmotically driven mini-pump via a lateral cerebral ventricle with morphine sulphate solution from day 2 post-partum for 5-7 days; the infusion rate was increased 2- or 2.5-fold each 40 h from 10 micrograms/h initially up to 50 micrograms/h; controls were infused with vehicle (1 microliter/h, twenty-eight rats) or were untreated (eight rats). 2. Maternal behaviour was disrupted in 27% of the morphine-treated rats; in rats that remained maternal morphine did not affect body weight or water intake but increased rectal temperature by 0.82 +/- 0.14 degrees C (mean +/- S.E.M.) across the first 4 days. 3. Weight gain of the litters of maternal morphine-treated rats was reduced by 32% during 7 days, predominantly in the first day of treatment when milk transfer was also reduced. Observation of pup behaviour during suckling showed decreased frequency of milk ejections on only the second day of morphine treatment. Plasma concentration of prolactin after 6 days was similar in maternal morphine-treated and control rats, but reduced by 90% in non-maternal morphine-treated rats, indicating normal control of prolactin secretion by suckling in morphine-treated rats. 4. Oxytocin and vasopressin contents, measured by radioimmunoassay, in the supraoptic and paraventricular nuclei and in the neurohypophysis were similar between fourteen maternal morphine-treated, twelve vehicle-treated and eight untreated lactating rats; thus exposure to morphine did not involve increased production and storage of oxytocin. 5. Distribution of [3H]morphine infused intracerebroventricularly into six virgin female rats for 6 days was measured by scintillation counting of tissue extracts. Morphine concentration in the hypothalamus and neurohypophysis was 2.7 and 12.8 micrograms/g, respectively, and in blood plasma 0.75 micrograms/g. Tolerance was not due to failure of morphine infusion. In addition, naloxone (5 mg/kg s.c.) provoked typical withdrawal reactions ('wet dog' shakes, defaecation, burrowing) in lactating rats infused with morphine for 5 days. 6. Pups were suckled onto seven maternal morphine-infused and five vehicle-infused rats anaesthetized with urethane for recording of intramammary and arterial blood pressures after treatment for 5 days. The incidence and pattern of milk ejections, and mammary gland sensitivity to oxytocin were similar in the two groups.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3411499      PMCID: PMC1192047          DOI: 10.1113/jphysiol.1988.sp016964

Source DB:  PubMed          Journal:  J Physiol        ISSN: 0022-3751            Impact factor:   5.182


  44 in total

1.  Control of food intake in the lactating rat: role of suckling and hormones.

Authors:  A S Fleming
Journal:  Physiol Behav       Date:  1976-11

2.  Effects of chronic morphine administration on pregnant rats and their offspring.

Authors:  I S Zagon; P J McLaughlin
Journal:  Pharmacology       Date:  1977       Impact factor: 2.547

3.  The milk-ejection reflex of the rat: an intermittent function not abolished by surgical levels of anaesthesia.

Authors:  D W Lincoln; A Hill; J B Wakerley
Journal:  J Endocrinol       Date:  1973-06       Impact factor: 4.286

4.  Diuretic effect of chronic morphine treatment in rats.

Authors:  C Marchand; G Denis
Journal:  J Pharmacol Exp Ther       Date:  1968-08       Impact factor: 4.030

5.  Opiate inhibition of peptide release from the neurohumoral terminals of hypothalamic neurones.

Authors:  G Clarke; P Wood; L Merrick; D W Lincoln
Journal:  Nature       Date:  1979-12-13       Impact factor: 49.962

6.  Effects of cholinoceptor antagonists on the suckling-induced and experimentally evoked release of oxytocin.

Authors:  G Clarke; C H Fall; D W Lincoln; L P Merrick
Journal:  Br J Pharmacol       Date:  1978-07       Impact factor: 8.739

7.  Characterization of an antiserum used in a radioimmunoassay for arginine-vasopressin: implications for reference standards.

Authors:  W G North; F T LaRochelle; J Haldar; W H Sawyer; H Valtin
Journal:  Endocrinology       Date:  1978-12       Impact factor: 4.736

8.  Sites of action of morphine involved in the development of physical dependence in rats. II. Morphine withdrawal precipitated by application of morphine antagonists into restricted parts of the ventricular system and by microinjection into various brain areas.

Authors:  E Laschka; H Teschemacher; P Mehraein; A Herz
Journal:  Psychopharmacologia       Date:  1976-03-16

9.  Modulation of prolactin, luteinizing hormone (LH) and follicle stimulating hormone (FSH) secretion by LHRH and bromocriptine (CB154) in the hypophysectomized pituitary-grafted male rat and its effect on testicular LH receptors and testosterone output.

Authors:  A S McNeilly; D M de Kretser; R M Sharpe
Journal:  Biol Reprod       Date:  1979-08       Impact factor: 4.285

10.  Differential effects of various opioid peptides on vasopressin and oxytocin release from the rat pituitary in vitro.

Authors:  D Maysinger; I Vermes; F Tilders; B R Seizinger; C Gramsch; V Höllt; A Herz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-12       Impact factor: 3.000

View more
  16 in total

Review 1.  The physiological costs of reproduction in small mammals.

Authors:  John R Speakman
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2008-01-27       Impact factor: 6.237

2.  Naloxone excites oxytocin neurones in the supraoptic nucleus of lactating rats after chronic morphine treatment.

Authors:  R J Bicknell; G Leng; D W Lincoln; J A Russell
Journal:  J Physiol       Date:  1988-02       Impact factor: 5.182

3.  Apamin increases post-spike excitability of supraoptic nucleus neurons in anaesthetized morphine-naïve rats and morphine-dependent rats: consequences for morphine withdrawal excitation.

Authors:  Philip M Bull; John A Russell; Victoria Scott; Colin H Brown
Journal:  Exp Brain Res       Date:  2011-06-14       Impact factor: 1.972

4.  Local morphine withdrawal increases c-fos gene, Fos protein, and oxytocin gene expression in hypothalamic magnocellular neurosecretory cells.

Authors:  L E Johnstone; C H Brown; H K Meeren; C L Vuijst; P J Brooks; G Leng; J A Russell
Journal:  J Neurosci       Date:  2000-02-01       Impact factor: 6.167

5.  Effects of the endogenous opioid peptide, endomorphin 1, on supraoptic nucleus oxytocin and vasopressin neurones in vivo and in vitro.

Authors:  N Doi; C H Brown; H D Cohen; G Leng; J A Russell
Journal:  Br J Pharmacol       Date:  2001-03       Impact factor: 8.739

Review 6.  The effects of opioids and opioid analogs on animal and human endocrine systems.

Authors:  Cassidy Vuong; Stan H M Van Uum; Laura E O'Dell; Kabirullah Lutfy; Theodore C Friedman
Journal:  Endocr Rev       Date:  2009-11-10       Impact factor: 19.871

7.  Morphine tolerance and inhibition of oxytocin secretion by kappa-opioids acting on the rat neurohypophysis.

Authors:  J A Russell; J E Coombes; G Leng; R J Bicknell
Journal:  J Physiol       Date:  1993-09       Impact factor: 5.182

8.  Effects of the selective kappa-opioid agonist U50,488 upon the electrical activity of supraoptic neurones in morphine-tolerant and morphine-naive rats.

Authors:  K M Pumford; J A Russell; G Leng
Journal:  Exp Brain Res       Date:  1993       Impact factor: 1.972

9.  Morphine actions on supraoptic oxytocin neurones in anaesthetized rats: tolerance after i.c.v. morphine infusion.

Authors:  K M Pumford; G Leng; J A Russell
Journal:  J Physiol       Date:  1991       Impact factor: 5.182

10.  Rapid estradiol-17beta modulation of opioid actions on the electrical and secretory activity of rat oxytocin neurons in vivo.

Authors:  Colin H Brown; Paula J Brunton; John A Russell
Journal:  Neurochem Res       Date:  2007-10-25       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.